title: Protective effects of gallic acid on hepatic lipid peroxide metabolism, glycoprotein components and lipids in streptozotocin-induced type II diabetic Wistar rats.
abstract: We evaluated the protective effects of gallic acid (3,4,5-trihydroxybenzoic acid) on hepatic lipid peroxidation products, antioxidants, glycoprotein components, and lipids in streptozotocin-induced type II diabetic rats. To induce type II diabetes, rats were injected with streptozotocin intraperitoneally at a single dose of 40 mg/kg. Gallic acid (10 and 20 mg/kg) treatment was given to diabetic rats orally using an intragastric tube daily for 21 days. Streptozotocin-induced diabetic rats showed a significant increase in the levels of blood glucose, hepatic lipid peroxidation products, glycoprotein components, lipids, and the activity of HMG-CoA reductase and a significant decrease in the levels of plasma insulin and liver glycogen. In addition to this, the activities/levels of hepatic antioxidants were decreased in diabetic rats. Gallic acid (10 and 20 mg/kg) treatment showed significant protective effects on all the biochemical parameters studied in diabetic rats. Thus, our study shows the antihyperglycemic, antilipid peroxidative, antioxidant, and antilipidemic effects of gallic acid in streptozotocin-induced type II diabetic rats. A diet containing gallic acid may be beneficial to type II diabetic patients.
authors.affiliation: Department of Biochemistry and Biotechnology, Annamalai University, Annamalai Nagar-608 002, India.
authors.forename: V R
authors.initials: VR
authors.lastname: Punithavathi
authors.forename: P
authors.initials: P
authors.lastname: Stanely Mainzen Prince
authors.forename: M R
authors.initials: MR
authors.lastname: Kumar
authors.forename: C J
authors.initials: CJ
authors.lastname: Selvakumari
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D005707:Gallic Acid / Q000627:therapeutic use*; D006023:Glycoproteins / Q000097:blood* / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D015227:Lipid Peroxidation / Q000187:drug effects*; D008054:Lipid Peroxides / Q000097:blood; D008112:Liver Glycogen / Q000032:analysis; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D014280:Triglycerides / Q000097:blood
chemical_list: D000975:Antioxidants; D001786:Blood Glucose; D006023:Glycoproteins; D007004:Hypoglycemic Agents; D008054:Lipid Peroxides; D008112:Liver Glycogen; D014280:Triglycerides; D013311:Streptozocin; D005707:Gallic Acid